Monday, 7 July 2014

Scottish Medicines Consortium issues positive advice for Forxiga® (dapagliflozin) use as part of a triple therapy regimen for type 2 diabetes 

The Scottish Medicines Consortium has issued guidance stating that Forxiga® (dapagliflozin), AstraZeneca’s first-in-class sodium-glucose co-transporter 2 (SGLT2) inhibitor for type 2 diabetes, is now accepted for restricted use within NHS Scotland as part of a triple therapy in combination with metformin and sulphonylurea, as an alternative to dipeptidyl peptidase-4 (DPP-4) inhibitors.3 (AstraZeneca)

No comments:

Post a Comment